KMTS NASDAQ Week ended 31 Jul 2026

Weekly Investor Report

Kestra Medical Technologies, Ltd. Common Stock · Healthcare · Medical Instruments & Supplies

Open interactive chart View report data
Latest close 22.83 USD
8.4% latest week
Weekly setup

Weak trend

The weekly trend is not active. Price is 1.3% above the Trend Line and sits at 54.9% of its 52-week range. The latest completed week returned 8.4%, after a -15.4% four-week move. The latest factor snapshot indicates quality ranks weakly versus its universe; growth ranks strongly; valuation is expensive relative to peers. The latest news-sentiment score is 50/100. Near-term considerations: volume confirmation is below normal; earnings are due in 39d.

Setup score 27 out of 100
Latest Close 22.83 USD 31 Jul 2026
1W Return 8.4% latest completed week
4W Return -15.4% short-term follow-through
12W Return 8.5% quarterly tape
Trend Breadth 36.5% 19 of 52 weeks active
Volume Ratio 0.9x vs 13-week average
What is working
  • Price is above the Trend Line, keeping the weekly tape constructive.
  • Price is above Fair Value, showing premium demand versus the model.
  • Activity pressure is positive on the latest completed week.
What could go wrong
  • The trend backdrop is inactive, so price action has not confirmed a constructive regime.
  • Activity pressure is weak, so confirmation is not yet broad enough.
  • 2 reversal markers appear in the recent smart-money tape.
  • The share remains more than 20% below its 52-week high.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through 8.4% Latest completed week; four-week move -15.4%. Indicator stack 20/63 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. News sentiment 50/100 50 relevant articles in the latest sentiment read. Event risk 39d Next report is scheduled for 10 Sep 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is not active. Price is 1.3% above the Trend Line and sits at 54.9% of its 52-week range. The latest completed week returned 8.4%, after a -15.4% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.9x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.4312-week average 0.19

12-week confirmation

Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure6/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership2/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.43Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers22 reversal markers

No recent accumulation markers. 2 reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -15.4% over four weeks, 8.5% over 12 weeks, and 48.4% over one year. The current trend has remained active for 0 consecutive weeks.

Performance by holding period

1W8.4%
4W-15.4%
12W8.5%
26W-7.5%
52W48.4%
Active trend streak0 weeks
Active weeks in one year19
Trend breadth36.5%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure0.68Latest activity-pressure read.
Pressure change4.4%Four-week change in activity pressure.
Leadership-8.58Latest relative-leadership reading.
RS change-254.3%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality ranks weakly versus its universe; growth ranks strongly; valuation is expensive relative to peers.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 30 Apr 2026 Field coverage 85% Model confidence 85%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength15/100Blend of value, momentum, and quality. Underlying universe rank 86; rank 1 is best.
Value19/100Relative valuation strength. Underlying universe rank 82; rank 1 is best.
Quality11/100Profitability and accounting quality. Underlying universe rank 90; rank 1 is best.
Momentum79/100Medium-term price momentum. Underlying universe rank 22; rank 1 is best.
Growth87/100Revenue and earnings growth. Underlying universe rank 14; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
13.0x
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-4.1%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
51.4%
Gross profit retained from each unit of revenue.
Operating margin
-132.8%
Operating profit retained from revenue.
Free-cash-flow margin
-49.2%
Free cash flow generated from revenue.
Return on invested capital
-57.7%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
59.0%
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
5/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
0.0%
Cash dividends relative to market value.
Buyback yield
-12.1%
Net share repurchases relative to market value.
Shareholder yield
-12.1%
Dividend yield plus net buyback yield.
Net debt / EBITDA
0.7x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Insider activity-

No recent insider transactions are stored for this company.

News sentiment50/100

Weighted news tone is neutral across 50 relevant articles.

6 positive · 36 neutral · 8 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings39dNext report is scheduled for 10 Sep 2026; event risk rises as the date approaches.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-23.9%Distance below the 52-week high.
13-week volatility11.3%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher11 of 2615 weeks finished lower.
Best week+32.6%Week of 26 Jun.
Worst week-17.2%Week of 13 Mar.
Latest week+8.4%Week of 31 Jul.

Shape of recent returns

Strong gains6
Modest gains5
Flat weeks0
Modest losses7
Sharp losses8
Recent vol11.3%13-week weekly-return volatility.
Base vol10.2%52-week weekly-return volatility.
Up/down split27/25Count of positive and negative weeks in the 52-week window.
Average skew8.5% / -6.5%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape29/100

Trend, activity pressure, participation, and risk combine to a 29/100 tape read.

 Indicator analysis26/100

Latest 12-week confirmation: trend 0/12, activity pressure 6/12, relative leadership 2/12.

Activity pressure 0.43; 2 reversal markers Factors28/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 88; Small Cap Core rank 88 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Sentiment50/100

Weighted news tone is neutral across 50 relevant articles.

Kestra Medical (KMTS) executive files Rule 144 notice for potential stock sale Insiders50/100

No recent insider transaction evidence is stored.

 Earnings39d

Next report is scheduled for 10 Sep 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
31 Jul 202622.83 USD8.4%22.53 USD22.16 USD0.68-8.581.5MOff
24 Jul 202621.06 USD-13.8%22.58 USD22.15 USD0.92-14.961.5MOff
17 Jul 202624.42 USD-6.0%22.78 USD22.16 USD1.21-2.892.5MOff
10 Jul 202625.99 USD-3.7%22.88 USD22.13 USD0.94-0.602.5MOff
3 Jul 202626.98 USD2.1%22.89 USD22.08 USD0.655.562.1MOff
26 Jun 202626.43 USD32.6%22.79 USD22.00 USD0.304.832.7MOff
19 Jun 202619.93 USD-4.4%22.81 USD21.94 USD-0.06-24.301.1MOff
12 Jun 202620.85 USD7.5%23.01 USD21.97 USD-0.17-18.761.4MOff
5 Jun 202619.40 USD-8.7%23.15 USD21.99 USD-0.38-22.861.9MOff
29 May 202621.26 USD-1.8%23.38 USD22.03 USD-0.49-19.78884.4KOff
22 May 202621.64 USD9.2%23.58 USD22.04 USD-0.57-16.641.4MOff
15 May 202619.82 USD-5.8%23.73 USD22.04 USD-0.57-23.281.4MOff
8 May 202621.05 USD-3.5%23.89 USD22.08 USD-0.47-19.601.4MOff
1 May 202621.82 USD-2.8%23.92 USD22.10 USD-0.60-12.851.1MOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.